Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumifyâ„¢ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumifyâ„¢ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Ocular redness
Timeframe: 5 minutes after application of eye drop
Ocular redness
Timeframe: 15 minutes after application of eye drop
Ocular redness
Timeframe: 30 minutes after application of eye drop
Ocular redness
Timeframe: 60 minutes after application of eye drop
Intraocular pressure
Timeframe: 60 minutes after application of eye drop